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INTRODUCTION
Recently, the clinical use of [
18F]FDG PET or PET/CT has rapidly 
increased as a management tool for sta  ging or localization of 
metastatic disease in patients with various malignancies. Uptake 
of FDG in the normal thyroid gland is very low and is usually 
not visualized on whole-body PET or PET/CT [1]. Occasionally, 
thyroid incidentalomas are shown on PET or PET/CT as a focal 
or diffuse increase in FDG uptake. The clinical issue is whether 
or not thyroid in  ci  dentalomas are benign or malignant. Consi-
dering the con  venience and in  creased use of PET or PET/CT in 
pre-treatment assess  ment of patients with cancer, the clinical 
sig  ni  fi  cance of thyroid inci  den  talomas is an important issue. 
Until now, many investigators have shown the results which 
have focused on the incidence of thyroid incidentalomas and 
the rate of malignancies associated with thyroid incidentalo-
mas on PET or PET/CT in patients with malignancy. Based on 
our experience, the incidence of thyroid incidentalomas in pa-
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Objective: Considering the increased use of [
18F]FDG PET or PET/CT, the clinical significance of thyroid incidentalomas is 
the subject of controversy. The aim of this study was to determine the incidence of malignancies associated with thyroid 
incidentalomas detected by pre-treatment PET or PET/CT in patients with cervical cancer.
Methods: We retrospectively reviewed the medical records of patients with cervical cancer who had thyroid incidentalomas de-
tected by pre-treatment PET or PET/CT and were treated at our institute between January 2001 and December 2009.
Results: Of 327 patients who underwent pre-treatment PET or PET/CT, 33 patients had thyroid incidentalomas (10.1%) and 4 
patients were diagnosed with thyroid malignancies by percutaneous needle aspiration (PCNA) or surgery. To put it concretely, 
of 33 patients with thyroid incidentaloma, 16 patients had a diffuse uptake and 17 patients had a focal uptake. Four of 17 patients 
with focal uptake were diagnosed with thyroid malignancies (23.5%). One patient with a focal uptake had an atypical cell based 
on PCNA, but did not undergo additional studies. The mean SUVmax of thyroid malignancies did not differ from that of benign 
thyroid diseases.
Conclusion: Thyroid incidentalomas are frequently detected by pre-treatment PET or PET/CT in patients with cervical cancer. 
Focal uptake on PET or PET/CT has a high risk of thyroid cancer.
Keywords: Cervical cancer, Fluorodeoxyglucose F18, Positron-emission tomography, Positron-emission tomography and 
computed tomography, Histological confirmation, Thyroid incidentalomas
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tients with cervical cancer is higher than expected. However, 
there are no studies which have focused on the patients with 
cervical cancer. 
In the current study we determined the incidence of thyroid 
incidentalomas and the rate of malignancies associated with 
thyroid incidentalomas detected by pre-treatment PET or PET/
CT in patients with cervical cancer. 
MATERIALS AND METHODS
1. Patients
The medical records of patients with cervical cancer who 
had thyroid incidentalomas by pre-treatment PET or PET/CT 
and were treated at our institute between January 2001 and 
December 2009 were reviewed retrospectively. Age, cervical 
cancer stage, type of thyroid incidentalomas (focal and dif-
fuse), the maximal standardized uptake value (SUVmax) of the 
thyroid incidentalomas, thyroid ultrasonography (USG) find-
ings, serum thyroid-stimulating hormone (TSH) level, percuta-
neous needle aspiration (PCNA) of the thyroid incidentalomas 
results, and final biopsy results from lobectomy or thyroidec-
tomy specimens were obtained. Approval from the Institu-
tional Review Board was obtained for this retrospective study 
(K-1009-002-071). 
2. PET or PET/CT evaluation 
Until September 2005, PET was performed on an advance 
HR+ Scanner (General Electric, Waukesha, WI, USA). After Sep-
tember 2005, we used the following PET/CT scanners: Bio  graph 
6 (Siemens Medical Solutions, Malvern, PA, USA); or Discovery 
LS (General Electric Medical Systems, Milwaukee, WI, USA). 
Each scan was obtained following the protocol. Patients were 
fasted at least 6-hour before the PET acquisition. Intravenous 
injection of 440±60 MBq (range, 165 to 758 MBq) of FDG was 
followed by a tracer up take phase of about 60 minutes, dur-
ing which the patients sat in a quiet room without talking. 
The CT scan was performed before emission PET scans. The 
current of the CT tube was adjusted according to patient 
weight. The CT data were resized from a 512×512 matrix to a 
128×128 matrix to match the PET data in order to generate 
a CT transmission map and to fuse images. PET emission data 
were acquired for five to seven bed positions, typically from 
the base of the skull through the upper thigh. PET images 
were reconstructed using CT for attenuation correction with 
the ordered-subsets expectation maximization algorithm (two 
iterations, eight subsets) and a 5-mm Gaussian filter using a 
128×128 matrix. 
Thyroid incidentalomas was defined as a newly identified 
thyroid lesion on PET or PET/CT in a patient without a previ-
ous, known history of thyroid disease. FDG uptake in less than 
1 lobe was defined as a focal lesion, whereas uptake in the 
entire thyroid gland was considered a diffuse pattern [2]. 
3. Ultrasonographic evaluation 
Thyroid nodules satisfying any one of the following condi-
tions were classified as malignant: 1) hypoechogenicity, 2) 
taller shape, 3) ill-defined margin, 4) central vascularity, 5) 
incomplete halo, and 6) micro- or macro-calcification [3,4]. 
Cases that did not satisfy any of those six criteria were consid-
ered as benign nodule on USG examinations. 
4. Criteria for thyroid PCNA cytology
PCNA was performed using a 21-guage needle on a 10-mL 
syringe under US guidance. Specimens were smeared on glass 
slides and stained using the Papanicolaou method. A cytolog-
ic diagnosis was made by experienced cytopathologists in our 
institution. Cytologic diagnosis was as followings; 1) nondiag-
nostic applies to specimens that are unsatisfactory owing to 
blood, overly thick or air dried smears, or an inadequate num-
ber of follicular cells; 2) benign was made by cytologic find-
ings of an adequately cellular specimen composed of varying 
proportions of colloid and benign follicular cells arranged as 
macrofollicles and macrofollicle fragments; 3) atypia of unde-
termined significance (AUS) was diagnosed when the results 
of PCNA cytology are not easily classified into the benign, 
suspicious, or malignant categories; 4) follicular neoplasm 
was made by cytologic findings of high cellularity and colloid 
is scant or absent; 5) suspicious for malignancy was classified 
when only 1 or 2 characteristic features of papillary thyroid 
carcinoma are presented or a malignant diagnosis cannot be 
made with certainty; 6) malignant was used whenever the cy-
tomorphologic features are conclusive for malignancy [5]. 
5. Statistical analysis
Data were expressed as the percentage of focal and diffuse 
incidental thyroid FDG uptake among the population. The 
difference in SUVmax between benign and malignant groups 
was analyzed by a Student’s t-test, and significance was set at 
a p<0.05. Data were analyzed using SPSS ver. 13.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Total 1,271 patients were newly diagnosed as cervical cancer, 
and 327 patients underwent pre-treatment PET or PET/CT dur-
ing the study period. We recommended PET or PET/CT to all Thyroid incidentaloma in patients with cervical cancer
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patients before starting treatment; however, 75% of all patients 
did not undergo pre-treatment PET or PET/CT due to long wait-
ing time for evaluation or their own economic pro  blems. Of 
327 patients, 33 patients had thyroid incidentalo  mas (10.1%). 
Twenty nine of 33 patients (89.7%) had cervical cancer with 
early stage (Table 1). The mean SUVmax of patients with thyroid 
incidentaloma was 4.24 for diffuse uptake and 8.40 for focal 
uptake, without a statistical difference between these groups 
(p=0.08). 
Sixteen of 17 patients with focal uptake underwent thyroid 
USGs and PCNAs. Only one patient with diffuse uptake under-
went a thyroid PCNA and was diagnosed with thyroiditis. One 
patient with focal thyroid incidentalomas had an AUS based 
on the PCNA result, but did not undergo additional studies 
(Fig. 1). 
The results of PCNA in patients with focal uptake were as 
follows: nine patients had benign lesions; three patients had 
malignancies; two patients had follicular neoplasms; one 
patient had AUS; and one patient had normal thyroid tissue. 
Three patients with malignancies and one patient with follicu-
lar neoplasm based on PCNA underwent total thyroidectomy 
or lobectomy, all of whom were confirmed to have thyroid 
cancer. Therefore, 4 of 17 patients with focal uptake were 
diagnosed with thyroid cancer by PCNA or surgery (23.5%). 
One patient with follicular neoplasm refused additional treat-
ment. Three of four patients with thyroid malignancies had a 
Fig. 1. Flow chart of patient selection process. PET, [
18F]FDG PET; USG, ultrasoundgraphy; PCNA, percutaneous needle aspiration; AUS, atypia of 
undetermined sig  ni  ficance.
Table 1. Clinicopathologic characteristics of patients with thyroid 
incidentalomas on PET or PET/CT
Diffuse 
(n=16)
Focal 
(n=17)
p-value
Age (yr), mean±SD 53.81±10.80 56.29±10.69 NS
Stage (%)
   Stage I 5 (31.3) 6 (35.3)
   Stage II 11 (68.7) 7 (41.2)
   Stage III+IV 0 (0) 4 (23.5)
SUVmax, median (range) 3.6 (2.2-7.6) 4.3 (2.5-36.9)
PET, [
18F]FDG PET; SD, standard deviation; NS, not signi  ficant; SUVmax, 
maximal standard unit value.Won-Moo Lee, et al.
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relatively high SUVmax on pre-treatment PET or PET/CT (Table 
2). The mean SUVmax of patients with thyroid malignancies was 
higher than that of patients with benign masses, but the dif-
ference of SUVmax was statistically insignificant (17.8 vs. 6.16, 
respectively, p=0.056). 
DISCUSSION
Thyroid incidentalomas are defined as newly identified focal 
thyroid lesions encountered during imaging studies, including 
CT, MRI, and USG. Although some studies using high-resolution 
USG have reported the risk of cancer of thyroid incidentalo-
mas 1.5-10% [6], these modalities (CT, MRI, and USG) are not 
specific for thyroid malignancy [7]. 
The current widespread use of PET or PET/CT has resulted in 
an increase in the detection of thyroid incidentalomas. The in-
cidence of thyroid incidentalomas and the rate of malignancy 
associated with thyroid incidentalomas on PET or PET/CT var-
ies with the study population. Generally, the incidence of thy-
roid incidentalomas is 2-9% [3,8,9], and the rate of malignancy 
associated with focal thyroid incidentalomas is as high as 28-
64% [2,10]. Especially, some authors reported that the preva-
lence of thyroid incidentaloma in cancer screening group was 
about 3% and this value was not differ from metastasis work-
up group [9]. In another study, the authors showed the results 
that the incidence of thyroid incidentalomas in patients with 
gynecologic cancer is 10.4% and the rate of malignancy of dif-
fuse and focal thyroid incidentalomas is 9.7% [11]. 
In our study, thyroid incidentalomas were identified in 33 of 
327 patients with cervical cancer, corresponding to a preva-
lence of 10.1%. This finding is similar or higher than previously 
reported in the literature [3,8,9,11]. However, it was remark-
able that the incidence of malignancy in focal FDG uptake 
in patients with cervical cancer is 23.5% and which is higher 
than previous reports included all gynecologic malignancies 
[11]. 
Some studies have reported that the average SUVmax of malig-
nant lesions is significantly higher than benign lesions [9,11,12]. 
A recent study even showed the result that the size and visual 
grade on the PET/CT were the potent predictors for differenti-
ation of malignancy in focal thyroid incidentaloma rather than 
the mean SUVmax [13]. In this study, the mean SUVmax was 6.16 
for benign lesions and 17.8 for malignant lesions, with a mar-
ginal difference between the two groups (p=0.056). Although 
some authors suggest that the mean SUVmax of thyroid malig-
nancies were significantly higher than those of benign tumors 
(p<0.001) [9], the role of SUVmax in differentiating benign from 
malignant lesions is controversial, because the SUVmax overlaps 
between benign and malignancy and the study sample num-
Table 2. Characteristics of patients with focal thyroid incidentalomas on PET or PET/CT
No. SUVmax Thyroid USG Thyroid PCNA TSH Surgery Histology
1 2.5 Benign Benign (goiter) Normal Not done -
2 2.6 Benign Follicular neoplasm Normal Not done -
3 2.7 Cancer Malignancy (PC) Normal Not done -
4 3.2 Benign Benign (goiter) Normal Not done -
5 3.2 Benign Benign (HFC) Not done Not done -
6 3.6 Benign Benign (goiter) Not done Not done -
7 3.9 Not done Not done Not done Not done -
8 3.9 No mass Benign (thyroiditis) Elevation Not done -
9 4.3 Benign Benign (BFC) Not done Not done -
10 5.0 Benign Benign (goiter) Normal Not done -
11 5.4 Cancer AUS Normal Not done -
12 5.5 Cancer Normal Not done Not done -
13 9.2 Cancer Malignancy (PC) Normal TT+LND PC
14 9.6 Benign Benign (BFC) Not done Not done -
15 18.9 Benign Benign (goiter) Normal Not done -
16 22.4 Cancer Malignancy (PC) Normal TT+LND PC
17 36.9 Benign Follicular neoplasm Normal Lobectomy FC
PET, [
18F]FDG PET; SUVmax, maximal standard unit value; USG, ultrasonography; PCNA, percutaneous needle aspiration; TSH, thyroid stimulating 
hormone; PC, papillary carcinoma; HFC, hyperplastic follicular cell; BFC, benign follicular cell; AUS, atypia of undetermined significance; TT, total 
thyroidectomy; LND, lymph node dissection; FC, follicular car  cinoma.Thyroid incidentaloma in patients with cervical cancer
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ber has been small in most previous studies. 
We admit that our study has some limitations. First, PET or 
PET/CT produce functional images that reflect increase rates 
of glucose metabolism in tumor, and it has many pit-falls in 
clinical use. Second, the number of patients enrolled in this 
study was too small to induce a strong conclusion. Therefore, 
more data and large-scale studies are required to determine 
the clinical significance of thyroid incidentalomas in patients 
with cervical cancer. 
In conclusion, the incidence of thyroid incidentalomas de-
tected by PET or PET/CT in patients with cervical cancer was 
10.1%; approximately one-half of thyroid incidentalomas have 
focal uptake and one-half of thyroid incidentalomas have dif-
fuse uptake. The rate of malignancy of focal thyroid inciden-
talomas in patients with cervical cancer was 23.5% and this 
result was much higher than that in other gynecologic ma-
lignancies reported in the previous literature. Because of the 
high rate of malignancy, histological confirmation including 
PCNA in patients with focal thyroid incidentalomas is neces-
sary to distinguish between benign and malignant thyroid 
incidentalomas. SUVmax could be helpful to distinguish malig-
nant thyroid incidentaloma from benign ones.
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